



# Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

**23%**  
Net Sales Up

**32%**  
International Sales Up

**27%**  
Pharma and Life Science Chemicals Up

## Unaudited Financial Results for the Quarter ended 30th June, 2005

(Rs. in Million)

CONSOLIDATED			Particulars	JUBILANT ORGANOSYS LTD.		
Quarter Ended June 30 (Unaudited)	Year Ended March 31 (Audited)	2005		Quarter Ended June 30 (Unaudited)	Year Ended March 31 (Audited)	2005
2005	2004	2005		2005	2004	2005
2390	2027	8536	Domestic sales & services	2390	2027	8536
1164	881	4201	International sales	966	716	3644
<b>3554</b>	<b>2908</b>	<b>12737</b>	<b>Gross sales</b>	<b>3356</b>	<b>2743</b>	<b>12180</b>
(287)	(247)	(1034)	Less: Excise duty on sales	(287)	(247)	(1034)
<b>3267</b>	<b>2661</b>	<b>11703</b>	<b>Net sales</b>	<b>3069</b>	<b>2496</b>	<b>11146</b>
31	10	166	Other income	22	9	139
<b>3298</b>	<b>2671</b>	<b>11869</b>	<b>Total income</b>	<b>3091</b>	<b>2505</b>	<b>11285</b>
<b>2873</b>	<b>2085</b>	<b>9627</b>	<b>Total expenditure</b>	<b>2656</b>	<b>2036</b>	<b>9221</b>
33	(188)	(388)	a) (Increase)/Decrease in stock of manufactured goods	(31)	(118)	(249)
65	114	260	b) Cost of trading goods sold	64	114	252
1709	1139	5701	c) Raw & process materials consumed	1698	1136	5643
153	175	607	d) Stores, spares, chemicals, catalyst & packing material consumed	147	137	579
286	253	1023	e) Manufacturing expenses	286	253	1023
87	94	382	– Cost of power & fuel	75	84	350
191	191	807	– Other manufacturing expenses	156	162	671
349	307	1235	f) Staff cost	261	268	952
<b>425</b>	<b>586</b>	<b>2242</b>	<b>Operating profit before interest and depreciation</b>	<b>435</b>	<b>469</b>	<b>2064</b>
49	67	220	Interest (Net)	47	65	213
<b>376</b>	<b>519</b>	<b>2022</b>	<b>Operating profit before depreciation</b>	<b>388</b>	<b>404</b>	<b>1851</b>
111	94	381	Depreciation	100	84	348
<b>265</b>	<b>425</b>	<b>1641</b>	<b>Profit before tax</b>	<b>288</b>	<b>320</b>	<b>1503</b>
55	143	431	Provision for tax (including Deferred Tax & Fringe Benefits Tax and net of reversals)	52	102	370
<b>210</b>	<b>282</b>	<b>1210</b>	<b>Net profit after tax</b>	<b>236</b>	<b>218</b>	<b>1133</b>
(3)	13	18	Minority Interest	–	–	–
<b>213</b>	<b>269</b>	<b>1192</b>	<b>Net profit after Minority Interest</b>	<b>236</b>	<b>218</b>	<b>1133</b>
131.9	117.3	129.6	Paid-up share capital (Face value of the share is Rs.5/-)	131.9	117.3	129.6
–	–	4887	Reserves (excluding revaluation reserve)	–	–	4803
<b>8.16</b>	<b>11.47</b>	<b>49.39</b>	<b>Basic (Rs.)</b>	<b>9.04</b>	<b>9.29</b>	<b>46.94</b>
<b>7.43</b>	<b>11.16</b>	<b>46.77</b>	<b>Diluted (Rs.)</b>	<b>8.22</b>	<b>9.00</b>	<b>44.49</b>
11558244	8199496	11084586	Aggregate of non-promoter shareholding	11558244	8199496	11084586
43.80	34.95	42.78	– Number of shares	43.80	34.95	42.78
			– Percentage of shareholding			

### Notes:

- During the quarter, Paid-up Share Capital increased by Rs.2.37 million and Securities Premium by Rs.385.19 million consequent to allotment of equity shares of Rs.5 each at a price of Rs.818.23 per share on the conversion of bonds (FCCB 2004) of US \$ 8.65 million issued by the company in the financial year 2004-2005.
- During the quarter, the Company issued Zero Coupon Foreign Currency Convertible Bonds (FCCB 2005) amounting to US\$ 75 million on May 23, 2005, subject to an increase of up to a further US\$25 million pursuant to the option. The bondholders have an option to convert these bonds into Equity shares or Global Depository Shares (GDS) determined at an initial conversion price of Rs.1365.32 per share at a fixed rate of exchange of Rs.43.35 = US\$ 1., and subject to adjustments specified in the Offering Memorandum dated May 18, 2005. These bonds will be due for redemption on May 24, 2010 at 138.383% of the principal amount unless previously converted, redeemed or purchased and cancelled. The net proceeds are being used for Acquisitions, Overseas Investments, Capital Expenditure and other uses as permitted under the applicable laws or regulations. The conversion of these bonds as on date is Nil. The issue related expenses and proportionate amount of premium payable on redemption have been debited to Share Premium Account.
- During the quarter the Company incorporated a wholly owned subsidiary, Jubilant Pharma Pte Limited., in Singapore with an investment of U.S. \$ 11 million, to facilitate the acquisition of Trinity Laboratories Inc. in USA, alongwith its subsidiary company.

Place : Noida  
Dated : July 30, 2005

visit us at [www.jubl.com](http://www.jubl.com)

(Rs. in Million)

Segment Wise Revenue, Results & Capital Employed (Under Clause 41 of the Listing Agreement)						
CONSOLIDATED			Particulars	JUBILANT ORGANOSYS LTD.		
Quarter Ended June 30 (Unaudited)	Year Ended March 31 (Audited)	2005		Quarter Ended June 30 (Unaudited)	Year Ended March 31 (Audited)	2005
2005	2004	2005		2005	2004	2005
1506	1184	5020	<b>Segment revenue</b>	1306	1019	4463
1502	1302	5996	a. Pharmaceuticals & Life Science Chemicals	1504	1302	5996
560	452	1902	b. Industrial Chemicals	560	452	1902
<b>3568</b>	<b>2938</b>	<b>12918</b>	<b>Gross sales</b>	<b>3370</b>	<b>2773</b>	<b>12361</b>
14	30	181	Less : Inter segment revenue	14	30	181
287	247	1034	Less : Excise duty on sales	287	247	1034
<b>3267</b>	<b>2661</b>	<b>11703</b>	<b>Net sales</b>	<b>3069</b>	<b>2496</b>	<b>11146</b>
1447	1136	4841	a. Pharmaceuticals & Life Science Chemicals	1247	971	4284
1331	1129	5194	b. Industrial Chemicals	1333	1129	5194
489	396	1668	c. Performance Chemicals	489	396	1668
<b>3267</b>	<b>2661</b>	<b>11703</b>	<b>Total</b>	<b>3069</b>	<b>2496</b>	<b>11146</b>
222	322	1110	<b>Segment results (profit(+)/loss(-) before tax and interest from each segment)</b>	243	215	965
89	209	830	a. Pharmaceuticals & Life Science Chemicals	89	209	830
28	12	25	b. Industrial Chemicals	28	12	25
<b>339</b>	<b>543</b>	<b>1965</b>	<b>Total</b>	<b>360</b>	<b>436</b>	<b>1820</b>
49	67	220	Less : i. Interest	47	65	213
25	51	104	ii. Other un-allocable expenditure (net of un-allocable income)	25	51	104
<b>265</b>	<b>425</b>	<b>1641</b>	<b>Total profit before tax</b>	<b>288</b>	<b>320</b>	<b>1503</b>
6877	4940	6536	<b>Capital Employed (Segment assets less Segment liabilities)</b>	5727	3723	5275
3153	2866	2623	a. Pharmaceuticals & Life Science Chemicals	3151	2866	2623
568	508	533	b. Industrial Chemicals	568	508	533
<b>10598</b>	<b>8314</b>	<b>9692</b>	<b>Total Capital employed in segments</b>	<b>9446</b>	<b>7097</b>	<b>8431</b>
2796	925	(20)	Add: Un-allocable corporate assets less liabilities	3854	1895	1045
<b>13394</b>	<b>9239</b>	<b>9672</b>	<b>Total Capital employed in the Company</b>	<b>13300</b>	<b>8992</b>	<b>9476</b>

- Consolidated results include results for subsidiary companies, namely, Jubilant Pharma N.V., Pharmaceutical Services Incorporated N.V., PSI Supply N.V., Jubilant Organosys (USA) Inc., Jubilant Organosys (Shanghai) Ltd., Jubilant Biosys Ltd., Jubilant Chemsys Ltd. and Jubilant Clinsys Ltd.
- Segment revenue, results and capital employed include the respective amounts identifiable to each of the segments and allocated on reasonable basis. Other Unallocable expenditure includes expenses incurred on common services provided to the segments which are not directly allocable on an appropriate basis.
- Information on investors complaints for the quarter (Nos.): Opening Balance – 3, New – 58, Disposals – 60, Closing Balance – 1.
- The Limited Review of above unaudited financial results as required in clause 41 of listing agreement has been carried out by the Statutory Auditors.
- Figures for previous period / year have been regrouped / reclassified / restated, wherever necessary.
- The above Financial Results were taken on record by the Board of Directors at their meeting held on 30th July, 2005.

For Jubilant Organosys Ltd.

Shyam S Bhartia  
Chairman & Managing Director